| Document |
Document Title |
|
WO/2023/177250A1 |
The present invention relates to a novel heterocyclic inhibitor for histone deacetylase (HDAC), a novel therapeutic agent for HDAC-associated diseases, and a pharmaceutical composition comprising same. More specifically, a compound accor...
|
|
WO/2023/174397A1 |
Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.
|
|
WO/2023/171305A1 |
An unsaturated hydrocarbon scavenger according to one aspect of the present disclosure has at least one carbon-carbon double bond, and contains a metal-organic framework that has a metal and a ligand coordinated to the metal, wherein the...
|
|
WO/2023/172846A1 |
Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2023/166450A1 |
The present invention relates to a compound represented by chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof, and a pharmaceutical composition comprising same.
|
|
WO/2023/165168A1 |
The present invention relates to an application of a pyrazole derivative as a β 2 adrenergic receptor allosteric modulator, antagonist and agonist. An acetophenone or an acetophenone containing different substituents is used as an initi...
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/165334A1 |
The present invention provides keto amide derivatives and the pharmaceutical use thereof, belonging to the technical field of organic synthesis drugs. Specifically provided are a compound represented by formula I, or a pharmaceutically a...
|
|
WO/2023/165570A1 |
The present invention relates to a compound of formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition thereof, and a use of the compound...
|
|
WO/2023/160039A1 |
Disclosed in the present invention are a β-elemene derivative with an HDACi pharmacophore, and a preparation method therefor and the use thereof. Provided in the present invention are a β-elemene derivative with an HDACi pharmacophore ...
|
|
WO/2023/159317A1 |
The present description relates to a CB1 receptor inhibitor compound of Formula I or a pharmaceutically acceptable salt thereof for the treatment of a patient population with abdominal obesity hypertriglyceridemia and impaired glucose.
|
|
WO/2023/163140A1 |
The purpose of the present invention is to provide a compound that exhibits an H-PGDS inhibitory activity. The present invention relates to a compound expressed by formula [I] or a pharmaceutically acceptable salt thereof (in the formula...
|
|
WO/2023/161458A1 |
The present invention relates to a crystalline form of darolutamide and to the process for its preparation. Furthermore, the invention relates to the use of said crystalline form for the preparation of a pharmaceutical composition useful...
|
|
WO/2023/162836A1 |
The present invention provides: an active-ray-sensitive or radiation-sensitive resin composition comprising a resin (P) which can be decomposed by the action of an acid to increase the polarity thereof and a compound (Q) represented by a...
|
|
WO/2023/164057A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I) for the modulation of IL-17A. Compounds and pharmaceutical compositions of Formula (I) are useful for the treatment of inflammatory conditions, such ...
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/156402A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The com...
|
|
WO/2023/156886A1 |
Provided is a new organic metal complex that improves the light emission efficiency of a light-emitting device. The present invention provides an organic metal complex represented by general formula (G1). In the formula, X represents car...
|
|
WO/2023/158866A2 |
The disclosure includes a method of inhibiting a eukaryotic translation initiation factor 3e (eIF3e) comprising contacting the eIF3e with a compound or salt of the Formula I, where the variables, e.g., Y, Z, R, and R1R11 are defined here...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/150874A1 |
Crystalline Forms of a compound of Formula I are provided: (I) Crystalline Form C is among the crystalline Forms identified. Form C has an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Ɵ (±0....
|
|
WO/2023/019244A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
|
WO/2023/154519A1 |
Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/150663A1 |
Provided herein are inhibitors of IGF-1R, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said IGF-1R inhibitory compounds for the treatment of disease.
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143355A1 |
The present invention provide compounds of formula (I-a), the preparation method thereof, pharmaceutcal compositions comprising the compounds, and the pharmaceutical uses for the treatment of cancer, autoimmune diseases, inflammatory dis...
|
|
WO/2023/146897A1 |
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular dis...
|
|
WO/2023/141852A1 |
Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
|
|
WO/2023/142985A1 |
The present invention belongs to the technical field of drug synthesis. Disclosed is a preparation method for a TGF-β-inhibiting anti-tumor drug. Compared with preparation methods in the existing technology, the number of reaction steps...
|
|
WO/2023/130540A1 |
Provided are a pyrazol benzamide compound represented by formula (I), a preparation method therefor and an application thereof, wherein R 1 and R 2 are independently selected from hydrogen, alkyl, amino, nitro, halogen, alkoxy, trifluoro...
|
|
WO/2023/131969A1 |
The present invention relates to an improved process for the preparation of Luliconazole. The present invention also provides a novel intermediate 1-cyanomethylimidazole methanesulphonate of Formula (V), process for its preparation and i...
|
|
WO/2023/130043A1 |
Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-com...
|
|
WO/2023/125373A1 |
A method for preparing ruxolitinib intermediates, i.e. (R)-3-(4-halo-1H-pyrazol-1-yl)-3-cyclopentylpropionate (VI) and (R)-3-(4-halo-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (IX). In the method, 3-(4-halo-1H-pyrazol-1-yl)-3-cyclopent...
|
|
WO/2023/130050A1 |
Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment and/or management of pain and related conditions, including post-operative pain, pain incident to an incision or wound, chronic p...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/116812A1 |
The present disclosure provides a sulfonylurea compound. Specifically, provided are a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof in prep...
|
|
WO/2023/122289A1 |
A crystalline free acid form of (S)-4-(l-(3-(difluoromethyl)-l-methyl-5- (3-(trifluoromethyl)phenoxy)-lH-pyrazole-4-carboxamido)ethyl
) benzoic acid is provided. Methods of making and using the crystalline free acid form of (S)-4-( l-(3-...
|
|
WO/2023/118970A1 |
Disclosed is a system (100) and process (200) for recovery of Acrylonitrile (ACRN) from an ATBS monomer slurry. The system (100) comprises a first evaporator apparatus (104) and a second evaporator apparatus (109) connected in series and...
|
|
WO/2023/116884A1 |
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/115165A1 |
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/122782A2 |
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the...
|
|
WO/2023/111472A1 |
The present invention relates to a method for preparing 3,5-dinitropyrazole, comprising a step involving obtaining N-acetyl-3-nitropyrazole from pyrazole, and a step involving the sigmatropic rearrangement of the compound obtained.
|
|
WO/2023/110932A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, The com...
|
|
WO/2023/114977A1 |
Described herein are compounds useful as S1PR4 receptor antagonists, pharmaceutical compositions comprising said compounds, methods of making said compounds and pharmaceutical compositions, and methods of using said compounds and pharmac...
|
|
WO/2023/110871A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2023/114188A1 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/112722A1 |
The present invention addresses the problem of providing: a compound suitably used for forming an optical anisotropic membrane that has excellent reverse wavelength dispersion property and moist heat durability; a polymerizable compositi...
|
